Patents by Inventor Kento Tanaka

Kento Tanaka has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Patent number: 11952423
    Abstract: A novel antibody that can be used as an anti-tumor agent and an anti-tumor agent that comprises, as an active ingredient, a molecule containing such an antibody.
    Type: Grant
    Filed: May 16, 2023
    Date of Patent: April 9, 2024
    Assignees: MIE UNIVERSITY, DAIICHI SANKYO COMPANY, LIMITED
    Inventors: Hiroshi Shiku, Yasushi Akahori, Kento Tanaka, Ayaka Yatsu, Junya Ichikawa, Toshiaki Ohtsuka, Shiho Kozuma, Ryuji Hashimoto, Makiko Nakayama, Naoya Shinozaki, Kensuke Nakamura, Ichiro Watanabe, Shinji Furuzono
  • Publication number: 20230404456
    Abstract: An adjustment device is configured to collect estimation results of the estimated state of the occupant; determine whether or not it is necessary to check the state of the occupant on the basis of the estimation results; determine a behavior of the occupant on the basis of behavior determination information and set the state of the occupant when it is determined that it is necessary to check the state of the occupant; and output adjustment information for causing an occupant state estimating device to adjust a state estimation condition used for estimating the state of the occupant so that the estimation result of the state of the occupant becomes the set state of the occupant.
    Type: Application
    Filed: February 3, 2021
    Publication date: December 21, 2023
    Applicant: Mitsubishi Electric Corporation
    Inventor: Kento TANAKA
  • Publication number: 20230348616
    Abstract: An antibody that can be used as an anti-tumor agent and an anti-tumor agent comprises a molecule containing such an antibody. Such an antibody or a binding fragment thereof comprises: a heavy chain CDRH1 consisting of SEQ ID NO: 54, a heavy chain CDRH2 consisting of SEQ ID NO: 55, a heavy chain CDRH3 consisting of SEQ ID NO: 56, a light chain CDRL1 consisting of SEQ ID NO: 57 or a light chain CDRL1 consisting of an amino acid sequence derived from SEQ ID NO: 57 in which amino acid 7 is W and/or amino acid 8 is K, a light chain CDRL2 consisting of SEQ ID NO: 58, and a light chain CDRL3 consisting of SEQ ID NO: 59 or a light chain CDRL3 consisting of an amino acid sequence derived from SEQ ID NO: 59 in which amino acid 2 is A or S.
    Type: Application
    Filed: March 29, 2021
    Publication date: November 2, 2023
    Applicants: MIE UNIVERSITY, DAIICHI SANKYO COMPANY, LIMITED
    Inventors: Hiroshi SHIKU, Yasushi AKAHORI, Kento TANAKA, Ayaka YATSU, Junya ICHIKAWA, Toshiaki OHTSUKA, Shiho KOZUMA, Ryuji HASHIMOTO, Makiko NAKAYAMA, Naoya SHINOZAKI, Kensuke NAKAMURA, Ichiro WATANABE, Shinji FURUZONO
  • Publication number: 20230287121
    Abstract: A novel antibody that can be used as an anti-tumor agent and an anti-tumor agent that comprises, as an active ingredient, a molecule containing such an antibody.
    Type: Application
    Filed: May 16, 2023
    Publication date: September 14, 2023
    Applicants: MIE UNIVERSITY, DAIICHI SANKYO COMPANY, LIMITED
    Inventors: Hiroshi SHIKU, Yasushi AKAHORI, Kento TANAKA, Ayaka YATSU, Junya ICHIKAWA, Toshiaki OHTSUKA, Shiho OKZUMA, Ryuji HASHIMOTO, Makiko NAKAYAMA, Naoya SHINOZAKI, Kensuke NAKAMURA, Ichiro WATANABE, Shinji FURUZONO
  • Patent number: 10851162
    Abstract: It is intended to provide a therapeutic and/or prophylactic agent for transplant rejections, immunological diseases, allergic diseases, inflammatory diseases, thrombosis, cancers, etc., targeting human Orai1. The present invention provides, for example, a pharmaceutical composition comprising an antibody that specifically recognizes human Orai1 and has the activity of inhibiting human T cell activation.
    Type: Grant
    Filed: July 2, 2019
    Date of Patent: December 1, 2020
    Assignee: Daiichi Sankyo Company, Limited
    Inventors: Tomoaki Komai, Takako Kimura, Daichi Baba, Yoshikuni Onodera, Kento Tanaka, Takashi Kagari, Anri Aki, Nobumi Nagaoka
  • Publication number: 20190322740
    Abstract: It is intended to provide a therapeutic and/or prophylactic agent for transplant rejections, immunological diseases, allergic diseases, inflammatory diseases, thrombosis, cancers, etc., targeting human Orai1. The present invention provides, for example, a pharmaceutical composition comprising an antibody that specifically recognizes human Orai1 and has the activity of inhibiting human T cell activation.
    Type: Application
    Filed: July 2, 2019
    Publication date: October 24, 2019
    Applicant: Daiichi Sankyo Company, Limited
    Inventors: Tomoaki Komai, Takako Kimura, Daichi Baba, Yoshikuni Onodera, Kento Tanaka, Takashi Kagari, Anri Aki, Nobumi Nagaoka
  • Patent number: 10351624
    Abstract: It is intended to provide a therapeutic and/or prophylactic agent for transplant rejections, immunological diseases, allergic diseases, inflammatory diseases, thrombosis, cancers, etc., targeting human Orai1. The present invention provides, for example, a pharmaceutical composition comprising an antibody that specifically recognizes human Orai1 and has the activity of inhibiting human T cell activation.
    Type: Grant
    Filed: August 6, 2015
    Date of Patent: July 16, 2019
    Assignee: Daiichi Sankyo Company, Limited
    Inventors: Tomoaki Komai, Takako Kimura, Daichi Baba, Yoshikuni Onodera, Kento Tanaka, Takashi Kagari, Anri Aki, Nobumi Nagaoka
  • Publication number: 20170226203
    Abstract: It is intended to provide a therapeutic and/or prophylactic agent for transplant rejections, immunological diseases, allergic diseases, inflammatory diseases, thrombosis, cancers, etc., targeting human Orai1. The present invention provides, for example, a pharmaceutical composition comprising an antibody that specifically recognizes human Orai1 and has the activity of inhibiting human T cell activation.
    Type: Application
    Filed: August 6, 2015
    Publication date: August 10, 2017
    Applicant: Daiichi Sankyo Company, Limited
    Inventors: Tomoaki Komai, Takako Kimura, Daichi Baba, Yoshikuni Onodera, Kento Tanaka, Takashi Kagari, Anri Aki, Nobumi Nagaoka